112 related articles for article (PubMed ID: 15084979)
1. Pancreatic carcinogenesis: apoptosis and angiogenesis.
Onizuka S; Kawakami S; Taniguchi K; Fujioka H; Miyashita K
Pancreas; 2004 Apr; 28(3):317-9. PubMed ID: 15084979
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice.
Kisker O; Onizuka S; Becker CM; Fannon M; Flynn E; D'Amato R; Zetter B; Folkman J; Ray R; Swamy N; Pirie-Shepherd S
Neoplasia; 2003; 5(1):32-40. PubMed ID: 12659668
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis and antiangiogenic strategies in pancreatic cancer.
Fisher WE; Berger DH
Int J Gastrointest Cancer; 2003; 33(1):79-88. PubMed ID: 12909740
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D binding protein-macrophage activating factor inhibits HCC in SCID mice.
Nonaka K; Onizuka S; Ishibashi H; Uto Y; Hori H; Nakayama T; Matsuura N; Kanematsu T; Fujioka H
J Surg Res; 2012 Jan; 172(1):116-22. PubMed ID: 20855083
[TBL] [Abstract][Full Text] [Related]
5. Treatment of human pancreatic cancer in mice with angiogenic inhibitors.
Prox D; Becker C; Pirie-Shepherd SR; Celik I; Folkman J; Kisker O
World J Surg; 2003 Apr; 27(4):405-11. PubMed ID: 12658482
[TBL] [Abstract][Full Text] [Related]
6. Generation of multiple angiogenesis inhibitors by human pancreatic cancer.
Kisker O; Onizuka S; Banyard J; Komiyama T; Becker CM; Achilles EG; Barnes CM; O'Reilly MS; Folkman J; Pirie-Shepherd SR
Cancer Res; 2001 Oct; 61(19):7298-304. PubMed ID: 11585769
[TBL] [Abstract][Full Text] [Related]
7. The molecular mechanism of luteolin-induced apoptosis is potentially related to inhibition of angiogenesis in human pancreatic carcinoma cells.
Cai X; Lu W; Ye T; Lu M; Wang J; Huo J; Qian S; Wang X; Cao P
Oncol Rep; 2012 Oct; 28(4):1353-61. PubMed ID: 22825765
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model.
Zhang X; Galardi E; Duquette M; Delic M; Lawler J; Parangi S
Clin Cancer Res; 2005 Mar; 11(6):2337-44. PubMed ID: 15788685
[TBL] [Abstract][Full Text] [Related]
9. Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer.
Stephan S; Datta K; Wang E; Li J; Brekken RA; Parangi S; Thorpe PE; Mukhopadhyay D
Clin Cancer Res; 2004 Oct; 10(20):6993-7000. PubMed ID: 15501979
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia and angiogenesis in pancreatic cancer.
Garcea G; Doucas H; Steward WP; Dennison AR; Berry DP
ANZ J Surg; 2006 Sep; 76(9):830-42. PubMed ID: 16922908
[TBL] [Abstract][Full Text] [Related]
11. Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer.
Guha S; Eibl G; Kisfalvi K; Fan RS; Burdick M; Reber H; Hines OJ; Strieter R; Rozengurt E
Cancer Res; 2005 Apr; 65(7):2738-45. PubMed ID: 15805273
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of angiogenesis by vitamin D-binding protein: characterization of anti-endothelial activity of DBP-maf.
Kalkunte S; Brard L; Granai CO; Swamy N
Angiogenesis; 2005; 8(4):349-60. PubMed ID: 16400520
[TBL] [Abstract][Full Text] [Related]
13. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
Ischenko I; Guba M; Yezhelyev M; Papyan A; Schmid G; Green T; Fennell M; Jauch KW; Bruns CJ
Angiogenesis; 2007; 10(3):167-82. PubMed ID: 17486419
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis in pancreatic cancer: current research status and clinical implications.
Li S; Xu HX; Wu CT; Wang WQ; Jin W; Gao HL; Li H; Zhang SR; Xu JZ; Qi ZH; Ni QX; Yu XJ; Liu L
Angiogenesis; 2019 Feb; 22(1):15-36. PubMed ID: 30168025
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
Lu YY; Jing DD; Xu M; Wu K; Wang XP
World J Gastroenterol; 2008 Sep; 14(35):5403-11. PubMed ID: 18803351
[TBL] [Abstract][Full Text] [Related]
16. Anti-cancer effect of HS-345, a new tropomyosin-related kinase A inhibitor, on human pancreatic cancer.
Seo JH; Jung KH; Son MK; Yan HH; Ryu YL; Kim J; Lee JK; Hong S; Hong SS
Cancer Lett; 2013 Sep; 338(2):271-81. PubMed ID: 23587795
[TBL] [Abstract][Full Text] [Related]
17. Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis.
Kanda S; Mochizuki Y; Miyata Y; Kanetake H; Yamamoto N
J Natl Cancer Inst; 2002 Sep; 94(17):1311-9. PubMed ID: 12208896
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer.
Yuan P; Wang L; Wei D; Zhang J; Jia Z; Li Q; Le X; Wang H; Yao J; Xie K
Cancer; 2007 Dec; 110(12):2682-90. PubMed ID: 17973266
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer.
Nagaraju GP; Zhu S; Ko JE; Ashritha N; Kandimalla R; Snyder JP; Shoji M; El-Rayes BF
Cancer Lett; 2015 Feb; 357(2):557-65. PubMed ID: 25497868
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo anticancer efficacy of silibinin against human pancreatic cancer BxPC-3 and PANC-1 cells.
Nambiar D; Prajapati V; Agarwal R; Singh RP
Cancer Lett; 2013 Jun; 334(1):109-17. PubMed ID: 23022268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
